tadocizumab|Heavy
QVQLVQSGAEVKKPGSSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGV
IYPGSGGTNYNEKFKGRVTLTVDESTNTAYMELSSLRSEDTAVYFCARRD
GNYGWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
ICNVNHKPSNTKVDKKVEPKSCDKTH
tadocizumab|Light
DIQMTQTPSTLSASVGDRVTISCRASQDINNYLNWYQQKPGKAPKLLIYY
TSTLHSGVPSRFSGSGSGTDYTLTISSLQPDDFATYFCQQGNTLPWTFGQ
GTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
LSSPVTKSFNRGEC


denosumab|Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSG
ITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDP
GTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCL
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGT
QTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNST
FRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
denosumab|Light
EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIY
GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFG
QGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK
VDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
GLSSPVTKSFNRGEC


ipilimumab|Heavy
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTF
ISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTG
WLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
CNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
ipilimumab|Light
EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIY
GAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFG
QGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK
VDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
GLSSPVTKSFNRGEC


efungumab|Heavy-Light
 MAEVQLVES GAEVKKPGES LRISCKGSGC IISSYWISWV RQMPGKGLEW 
MGKIDPGDSY INYSPSFQGH VTISADKSIN TAYLQWNSLK ASDTAMYYCA 
RGGRDFGDSF DYWGQGTLVT VSSGGGGSGG GGSGGGGSDV VMTQSPSFLS 
AFVGDRITIT CRASSGISRY LAWYQQAPGK APKLLIYAAS TLQTGVPSRF 
SGSGSGTEFT LTINSLQPED FATYYCQHLN SYPLTFGGGT KVDIKRAAA 
LEhhhhhh	


abagovomab|Heavy
QVKLQESGAE LARPGASVKL SCKASGYTFT NYWMQWVKQR PGQGLDWIGA 50
IYPGDGNTRY THKFKGKATL TADKSSSTAY MQLSSLASED SGVYYCARGE 100
GNYAWFAYWG QGTTVTVSSA KTTPPSVYPL APGSAAQTNS MVTLGCLVKG 150
YFPEPVTVTW NSGSLSSGVH TFPAVLQSDL YTLSSSVTVP SSTWPSETVT 200
CNVAHPASST KVDKKIVPRD CGCKPCICTV PEVSSVFIFP PKPKDVLTIT 250
LTPKVTCVVV DISKDDPEVQ FSWFVDDVEV HTAQTQPREE QFNSTFRSVS 300
ELPIMHQDWL NGKEFKCRVN SAAFPAPIEK TISKTKGRPK APQVYTIPPP 350
KEQMAKDKVS LTCMITDFFP EDITVEWQWN GQPAENYKNT QPIMDTDGSY 400
FVYSKLNVQK SNWEAGNTFT CSVLHEGLHN HHTEKSLSHS PGK         443
abagovomab|Light
DIELTQSPAS LSASVGETVT ITCQASENIY SYLAWHQQKQ GKSPQLLVYN 50
AKTLAGGVSS RFSGSGSGTH FSLKIKSLQP EDFGIYYCQH HYGILPTFGG 100
GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150
DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200
STSPIVKSFN RNEC                                        214


stamulumab|Heavy
EVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	SYYMHWVRQA	PGQGLEWMGI
INPSGGSTSY	AQKFQGRVTM	TRDTSTSTVY	MELSSLRSED	TAVYYCARDE
NWGFDPWGQG	TLVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	ALGCLVKDYF
PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS	SSLGTQTYIC
NVNHKPSNTK	VDKKVEPKSC	DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT
LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT
LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTPPVLDS
DGSFFLYSKL	TVDKSRWQQG	NVFSCSVMHE	ALHNHYTQKS	LSLSPGK
stamulumab|Light
SYELTQPPSV	SVSPGQTASI	TCSGHALGDK	FVSWYQQKPG	QSPVLVIYDD
TQRPSGIPER	FSGSNSGNTA	TLTISGTQAM	DEADYYCQAW	DSSFVFGGGT
KVTVLGQPKA	APSVTLFPPS	SEELQANKAT	LVCLISDFYP	GAVTVAWKAD
SSPVKAGVET	TTPSKQSNNK	YAASSYLSLT	PEQWKSHRSY	SCQVTHEGST
VEKTVAPTEC	S			

		
iratumumab|Heavy
QVQLQQWGAG	LLKPSETLSL	TCAVYGGSFS	AYYWSWIRQP	PGKGLEWIGD
INHGGGTNYN	PSLKSRVTIS	VDTSKNQFSL	KLNSVTAADT	AVYYCASLTA
YWGQGSLVTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL	VKDYFPEPVT
VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT	QTYICNVNHK
PSNTKVDKKV	EPKSCDKTHT	CPPCPAPELL	GGPSVFLFPP	KPKDTLMISR
TPEVTCVVVD	VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ	YNSTYRVVSV
LTVLHQDWLN	GKEYKCKVSN	KALPAPIEKT	ISKAKGQPRE	PQVYTLPPSR
DELTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTTP	PVLDSDGSFF
LYSKLTVDKS	RWQQGNVFSC	SVMHEALHNH	TQKSLSLSPG	K
iratumumab|Light
DIQMTQSPTS	LSASVGDRVT	ITCRASQGIS	SWLTWYQQKP	EKAPKSLIYA
ASSLQSGVPS	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQQ	YDSYPITFGQ
GTRLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG
LSSPVTKSFN	RGEC			


tremelimumab|Heavy
QVQLVESGGG	VVQPGRSLRL	SCAASGFTFS	SYGMHWVRQA	PGKGLEWVAV
IWYDGSNKYY	ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCARDP
RGATLYYYYY	GMDVWGQGTT	VTVSSASTKG	PSVFPLAPCS	RSTSESTAAL
GCLVKDYFPE	PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVVTVPSSN
FGTQTYTCNV	DHKPSNTKVD	KTVERKCCVE	CPPCPAPPVA	GPSVFLFPPK
PKDTLMISRT	PEVTCVVVDV	SHEDPEVQFN	WYVDGVEVHN	AKTKPREEQF
NSTFRVVSVL	TVVHQDWLNG	KEYKCKVSNK	GLPAPIEKTI	SKTKGQPREP
QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTTPP
MLDSDGSFFL	YSKLTVDKSR	WQQGNVFSCS	VMHEALHNHY	TQKSLSLSPG
K				
tremelimumab|Light
DIQMTQSPSS	LSASVGDRVT	ITCRASQSIN	SYLDWYQQKP	GKAPKLLIYA
ASSLQSGVPS	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQQ	YYSTPFTFGP
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG
LSSPVTKSFN	RGEC			

 

canakinumab|Heavy
QVQLVESGGG VVQPGRSLRL SCAASGFTFS VYGMNWVRQA PGKGLEWVAI 
IWYDGDNQYY ADSVKGRFTI SRDNSKNTLY LQMNGLRAED TAVYYCARDL 
RTGPFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 
canakinumab|Light
EIVLTQSPDF QSVTPKEKVT ITCRASQSIG SSLHWYQQKP DQSPKLLIKY 
ASQSFSGVPS RFSGSGSGTD FTLTINSLEA EDAAAYYCHQ SSSLPFTFGP 
GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 
LSSPVTKSFN RGEC


otelixizumab|Heavy
EVQLLESGGG	LVQPGGSLRL	SCAASGFTFS	SFPMAWVRQA	PGKGLEWVST
ISTSGGRTYY	RDSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCAKFR
QYSGGFDYWG	QGTLVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY
ICNVNHKPSN	TKVDKKVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK
DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYAS
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV
YTLPPSRDEL	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTPPVL
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK
otelixizumab|Light
DIQLTQPNSV	STSLGSTVKL	SCTLSSGNIE	NNYVHWYQLY	EGRSPTTMIY
DDDKRPDGVP	DRFSGSIDRS	SNSAFLTIHN	VAIEDEAIYF	CHSYVSSFNV
FGGGTKLTVL	RQPKAAPSVT	LFPPSSEELQ	ANKATLVCLI	SDFYPGAVTV
AWKADSSPVK	AGVETTTPSK	QSNNKYAASS	YLSLTPEQWK	SHRSYSCQVT
HEGSTVEKTV	APTECS			


lucatumumab|Heavy
QVQLVESGGG	VVQPGRSLRL	SCAASGFTFS	SYGMHWVRQA	PGKGLEWVAV
ISYEESNRYH	ADSVKGRFTI	SRDNSKITLY	LQMNSLRTED	TAVYYCARDG
GIAAPGPDYW	GQGTLVTVSS	ASTKGPSVFP	LAPASKSTSG	GTAALGCLVK
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT
YICNVNHKPS	NTKVDKRVEP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPKP
KDTLMISRTP	EVTCVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTPPV
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK
lucatumumab|Light
DIVMTQSPLS	LTVTPGEPAS	ISCRSSQSLL	YSNGYNYLDW	YLQKPGQSPQ
VLISLGSNRA	SGVPDRFSGS	GSGTDFTLKI	SRVEAEDVGV	YYCMQARQTP
FTFGPGTKVD	IRRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK
VQWKVDNALQ	SGNSQESVTE	QDSKDSTYSL	SSTLTLSKAD	YEKHKVYACE
VTHQGLSSPV	TKSFNRGEC			


panobacumab|Heavy
EEQVVESGGG FVQPGGSLRL SCAASGFTFS PYWMHWVRQA PGKGLVWVSR  50
INSDGSTYYA DSVKGRFTIS RDNARNTLYL QMNSLRAEDT AVYYCARDRY 100
YGPEMWGQGT MVTVSSGSAS APTLFPLVSC ENSPSDTSSV AVGCLAQDFL 150
PDSITFSWKY KNNSDISSTR GFPSVLRGGK YAATSQVLLP SKDVMQGTDE 200
HVVCKVQHPN GNKEKNVPLP VIAELPPKVS VFVPPRDGFF GNPRKSKLIC 250
QATGFSPRQI QVSWLREGKQ VGSGVTTDQV QAEAKESGPT TYKVTSTLTI 300
KESDWLSQSM FTCRVDHRGL TFQQNASSMC VPDQDTAIRV FAIPPSFASI 350
FLTKSTKLTC LVTDLTTYDS VTISWTRQNG EAVKTHTNIS ESHPNATFSA 400
VGEASICEDD WNSGERFTCT VTHTDLPSPL KQTISRPKGV ALHRPDVYLL 450
PPAREQLNLR ESATITCLVT GFSPADVFVQ WMQRGQPLSP EKYVTSAPMP 500
EPQAPGRYFA HSILTVSEEE WNTGETYTCV VAHEALPNRV TERTVDKSTG 550
KPTLYNVSLV MSDTAGTCY                                   569
panobacumab|Light
DVVMTQSPLS LPVTLGQPAS ISCRSSQSLV YSDGNTYLNW FQQRPGQSPR  50
RLIYKVSNRD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCMQGTHWP 100
LTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219



milatuzumab|Heavy
QVQLQQSGSE	LKKPGASVKV	SCKASGYTFT	NYGVNWIKQA	PGQGLQWMGW
INPNTGEPTF	DDDFKGRFAF	SLDTSVSTAY	LQISSLKADD	TAVYFCSRSR
GKNEAWFAYW	GQGTLVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT
YICNVNHKPS	NTKVDKRVEP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPKP
KDTLMISRTP	EVTCVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTPPV
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK
milatuzumab|Light
DIQLTQSPLS	LPVTLGQPAS	ISCRSSQSLV	HRNGNTYLHW	FQQRPGQSPR
LLIYTVSNRF	SGVPDRFSGS	GSGTDFTLKI	SRVEAEDVGV	YFCSQSSHVP
PTFGAGTRLE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK
VQWKVDNALQ	SGNSQESVTE	QDSKDSTYSL	SSTLTLSKAD	YEKHKVYACE
VTHQGLSSPV	TKSFNRGEC			


veltuzumab|Heavy
QVQLQQSGAE	VKKPGSSVKV	SCKASGYTFT	SYNMHWVKQA	PGQGLEWIGA
IYPGMGDTSY	NQKFKGKATL	TADESTNTAY	MELSSLRSED	TAFYYCARST
YYGGDWYFDV	WGQGTTVTVS	SASTKGPSVF	PLAPSSKSTS	GGTAALGCLV
KDYFPEPVTV	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSVV	TVPSSSLGTQ
TYICNVNHKP	SNTKVDKRVE	PKSCDKTHTC	PPCPAPELLG	GPSVFLFPPK
PKDTLMISRT	PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	AKTKPREEQY
NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP
QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTTPP
VLDSDGSFFL	YSKLTVDKSR	WQQGNVFSCS	VMHEALHNHY	TQKSLSLSPG
K	
veltuzumab|Light		
DIQLTQSPSS	LSASVGDRVT	MTCRASSSVS	YIHWFQQKPG	KAPKPWIYAT
SNLASGVPVR	FSGSGSGTDY	TFTISSLQPE	DIATYYCQQW	TSNPPTFGGG
TKLEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD
NALQSGNSQE	SVTEQDSKDS	TYSLSSTLTL	SKADYEKHKV	YACEVTHQGL
SSPVTKSFNR	GEC			


tanezumab|Heavy
QVQLQESGPG	LVKPSETLSL	TCTVSGFSLI	GYDLNWIRQP	PGKGLEWIGI
IWGDGTTDYN	SAVKSRVTIS	KDTSKNQFSL	KLSSVTAADT	AVYYCARGGY
WYATSYYFDY	WGQGTLVTVS	SASTKGPSVF	PLAPCSRSTS	ESTAALGCLV
KDYFPEPVTV	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSVV	TVPSSNFGTQ
TYTCNVDHKP	SNTKVDKTVE	RKCCVECPPC	PAPPVAGPSV	FLFPPKPKDT
LMISRTPEVT	CVVVDVSHED	PEVQFNWYVD	GVEVHNAKTK	PREEQFNSTF
RVVSVLTVVH	QDWLNGKEYK	CKVSNKGLPS	SIEKTISKTK	GQPREPQVYT
LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTPPMLDS
DGSFFLYSKL	TVDKSRWQQG	NVFSCSVMHE	ALHNHYTQKS	LSLSPGK
tanezumab|Light
DIQMTQSPSS	LSASVGDRVT	ITCRASQSIS	NNLNWYQQKP	GKAPKLLIYY
TSRFHSGVPS	RFSGSGSGTD	FTFTISSLQP	EDIATYYCQQ	EHTLPYTFGQ
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG
LSSPVTKSFN	RGEC			

		
Ustekinumab|Heavy
EVQLVQSGAE	VKKPGESLKI	SCKGSGYSFT	TYWLGWVRQM	PGKGLDWIGI
MSPVDSDIRY	SPSFQGQVTM	SVDKSITTAY	LQWNSLKASD	TAMYYCARRR
PGQGYFDFWG	QGTLVTVSSS	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY
ICNVNHKPSN	TKVDKRVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK
DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV
YTLPPSRDEL	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTPPVL
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK
Ustekinumab|Light
DIQMTQSPSS	LSASVGDRVT	ITCRASQGIS	SWLAWYQQKP	EKAPKSLIYA
ASSLQSGVPS	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQQ	YNIYPYTFGQ
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG
LSSPVTKSFN	RGEC			

		

Tigatuzumab|Heavy
EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	SYVMSWVRQA	PGKGLEWVAT
ISSGGSYTYY	PDSVKGRFTI	SRDNAKNTLY	LQMNSLRAED	TAVYYCARRG
DSMITTDYWG	QGTLVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY
ICNVNHKPSN	TKVDKRVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK
DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV
YTLPPSREEM	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTPPVL
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK
Tigatuzumab|Light
DIQMTQSPSS	LSASVGDRVT	ITCKASQDVG	TAVAWYQQKP	GKAPKLLIYW
ASTRHTGVPS	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQQ	YSSYRTFGQG
TKVEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD
NALQSGNSQE	SVTEQDSKDS	TYSLSSTLTL	SKADYEKHKV	YACEVTHQGL
SSPVTKSFNR	GEC			


Racotumomab|Heavy
QVQLQQSGAE LVKPGASVKL SCKASGYTFT SYDINWVRQR PEQGLEWIGW   50
IFPGDGSTKY NEKFKGKATL TTDKSSSTAY MQLSRLTSED SAVYFCARED  100
YYDNSYYFDY WGQGTTLTVS SAKTTPPSVY PLAPGSAAQT NSMVTLGCLV  150
KGYFPEPVTV TWNSGSLSSG VHTFPAVLQS DLYTLSSSVT VPSSPRPSET  200
VTCNVAHPAS STKVDKKIVP RDCGCKPCIC TVPEVSSVFI FPPKPKDVLT  250
ITLTPKVTCV VVDISKDDPE VQFSWFVDDV EVHTAQTQPR EEQFNSTFRS  300
VSELPIMHQD WLNGKEFKCR VNSAAFPAPI EKTISKTKGR PKAPQVYTIP  350
PPKEQMAKDK VSLTCMITDF FPEDITVEWQ WNGQPAENYK NTQPIMNTNG  400
SYFVYSKLNV QKSNWEAGNT FTCSVLHEGL HNHHTEKSLS HSPGK       445
Racotumomab|Light
DIQMTQTTSS LSASLGDRVT ISCRASQDIS NYLNWYQQKP DGTVKLLIYY   50
TSRLHSGVPS RFSGSGSGTD YSLTISNLEQ EDIATYFCQQ GNTLPWTFGG  100
GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI  150
DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT  200
STSPIVKSFN RNEC                                         214		


Blinatumomab|Light-Heavy-Heavy-Light
DIQLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDSYLNWY QQIPGQPPKL 50
LIYDASNLVS GIPPRFSGSG SGTDFTLNIH PVEKVDAATY HCQQSTEDPW 100
TFGGGTKLEI KGGGGSGGGG SGGGGSQVQL QQSGAELVRP GSSVKISCKA 150
SGYAFSSYWM NWVKQRPGQG LEWIGQIWPG DGDTNYNGKF KGKATLTADE 200
SSSTAYMQLS SLASEDSAVY FCARRETTTV GRYYYAMDYW GQGTTVTVSS 250
GGGGSDIKLQ QSGAELARPG ASVKMSCKTS GYTFTRYTMH WVKQRPGQGL 300
EWIGYINPSR GYTNYNQKFK DKATLTTDKS SSTAYMQLSS LTSEDSAVYY 350
CARYYDDHYC LDYWGQGTTL TVSSVEGGSG GSGGSGGSGG VDDIQLTQSP 400
AIMSASPGEK VTMTCRASSS VSYMNWYQQK SGTSPKRWIY DTSKVASGVP 450
YRFSGSGSGT SYSLTISSME AEDAATYYCQ QWSSNPLTFG AGTKLELKHH 500
HHHH


Conatumumab|Heavy
QVQLQESGPG	LVKPSQTLSL	TCTVSGGSIS	SGDYFWSWIR	QLPGKGLEWI
GHIHNSGTTY	YNPSLKSRVT	ISVDTSKKQF	SLRLSSVTAA	DTAVYYCARD
RGGDYYYGMD	VWGQGTTVTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT
QTYICNVNHK	PSNTKVDKRV	EPKSCDKTHT	CPPCPAPELL	GGPSVFLFPP
KPKDTLMISR	TPEVTCVVVD	VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ
YNSTYRVVSV	LTVLHQDWLN	GKEYKCKVSN	KALPAPIEKT	ISKAKGQPRE
PQVYTLPPSR	EEMTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTTP
PVLDSDGSFF	LYSKLTVDKS	RWQQGNVFSC	SVMHEALHNH	YTQKSLSLSP
GK			
Conatumumab|Light	
EIVLTQSPGT	LSLSPGERAT	LSCRASQGIS	RSYLAWYQQK	PGQAPSLLIY
GASSRATGIP	DRFSGSGSGT	DFTLTISRLE	PEDFAVYYCQ	QFGSSPWTFG
QGTKVEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLNNF	YPREAKVQWK
VDNALQSGNS	QESVTEQDSK	DSTYSLSSTL	TLSKADYEKH	KVYACEVTHQ
GLSSPVTKSF	NRGEC	


Obinutuzumab|Heavy
QVQLVQSGAE	VKKPGSSVKV	SCKASGYAFS	YSWINWVRQA	PGQGLEWMGR
IFPGDGDTDY	NGKFKGRVTI	TADKSTSTAY	MELSSLRSED	TAVYYCARNV
FDGYWLVYWG	QGTLVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY
ICNVNHKPSN	TKVDKKVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK
DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV
YTLPPSRDEL	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTPPVL
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPG
Obinutuzumab|Light  
DIVMTQTPLS	LPVTPGEPAS	ISCRSSKSLL	HSNGITYLYW	YLQKPGQSPQ
LLIYQMSNLV	SGVPDRFSGS	GSGTDFTLKI	SRVEAEDVGV	YYCAQNLELP
YTFGGGTKVE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK
VQWKVDNALQ	SGNSQESVTE	QDSKDSTYSL	SSTLTLSKAD	YEKHKVYACE
VTHQGLSSPV	TKSFNRGEC		

                                    
Rafivirumab|Heavy
EVQLVQSGAE	VKKPGSSVKV	SCKASGGTFN	RYTVNWVRQA	PGQGLEWMGG
IIPIFGTANY	AQRFQGRLTI	TADESTSTAY	MELSSLRSDD	TAVYFCAREN
LDNSGTYYYF	SGWFDPWGQG	TLVTVSSAST	KGPSVFPLAP	SSKSTSGGTA
ALGCLVKDYF	PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS
SSLGTQTYIC	NVNHKPSNTK	VDKRVEPKSC	DKTHTCPPCP	APELLGGPSV
FLFPPKPKDT	LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK
PREEQYNSTY	RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK
GQPREPQVYT	LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN
YKTTPPVLDS	DGSFFLYSKL	TVDKSRWQQG	NVFSCSVMHE	ALHNHYTQKS
LSLSPG
Rafivirumab|Light  
ESALTQPRSV  SGSPGQSVTI  SCTGTSSDIG  GYNFVSWYQQ  HPGKAPKLMI
YDATKRPSGV  PDRFSGSKSG  NTASLTISGL  QAEDEADYYC  CSYAGDYTPG
VVFGGGTKLT  VLGQPKAAPS  VTLFPPSSEE  LQANKATLVC  LISDFYPGAV
TVAWKADSSP  VKAGVETTTP  SKQSNNKYAA  SSYLSLTPEQ  WKSHRSYSCQ
VTHEGSTVEK  TVAPTECS      				


foravirumab|Heavy
EVQLVESGGG	AVQPGRSLRL	SCAASGFTFS	SYGMHWVRQA	PGKGLEWVAV
ILYDGSDKFY	ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCAKVA
VAGTHFDYWG	QGTLVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY
ICNVNHKPSN	TKVDKRVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK
DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV
YTLPPSREEM	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTPPVL
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPG
foravirumab|Light 
DIQMTQSPSS	LSASVGDRVT	ITCRASQGIR	NDLGWYQQKP	GKAPKLLIYA
ASSLQSGVPS	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQQ	LNSYPPTFGG
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG
LSSPVTKSFN	RGEC			


farletuzumab|Heavy 
EVQLVESGGG VVQPGRSLRL SCSASGFTFS GYGLSWVRQA PGKGLEWVAM   50
ISSGGSYTYY ADSVKGRFAI SRDNAKNTLF LQMDSLRPED TGVYFCARHG  100
DDPAWFAYWG QGTPVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD  150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY  200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK  250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS  300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV  350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL  400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK   449
farletuzumab|Light
DIQLTQSPSS LSASVGDRVT ITCSVSSSIS SNNLHWYQQK PGKAPKPWIY   50
GTSNLASGVP SRFSGSGSGT DYTFTISSLQ PEDIATYYCQ QWSSYPYMYT  100
FGQGTKVEIK RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ  150
WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE KHKVYACEVT  200
HQGLSSPVTK SFNRGEC                                      217


elotuzumab|Heavy 
EVQLVESGGG LVQPGGSLRL SCAASGFDFS RYWMSWVRQA PGKGLEWIGE   50
INPDSSTINY APSLKDKFII SRDNAKNSLY LQMNSLRAED TAVYYCARPD  100
GNYWYFDVWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD  150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY  200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK  250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS  300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV  350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL  400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK   449
elotuzumab|Light
DIQMTQSPSS LSASVGDRVT ITCKASQDVG IAVAWYQQKP GKVPKLLIYW   50
ASTRHTGVPD RFSGSGSGTD FTLTISSLQP EDVATYYCQQ YSSYPYTFGQ  100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  200
LSSPVTKSFN RGEC                                         214


Necitumumab|Heavy
QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGDYYWSWIR QPPGKGLEWI   50
GYIYYSGSTD YNPSLKSRVT MSVDTSKNQF SLKVNSVTAA DTAVYYCARV  100
SIFGVGTFDY WGQGTLVTVS SASTKGPSVL PLAPSSKSTS GGTAALGCLV  150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ  200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK  250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY  300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP  350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP  400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG  450
K                                                       451
Necitumumab|Light
EIVMTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD   50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCHQ YGSTPLTFGG  100
GTKAEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  200
LSSPVTKSFN RGEC                                         214


Vedolizumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKGSGYTFT SYWMHWVRQA PGQRLEWIGE  50
IDPSESNTNY NQKFKGRVTL TVDISASTAY MELSSLRSED TAVYYCARGG 100
YDGWDYAIDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELAG APSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                      451
Vedolizumab|Light
DVVMTQSPLS LPVTPGEPAS ISCRSSQSLA KSYGNTYLSW YLQKPGQSPQ  50
LLIYGISNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQGTHQP 100
YTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219


Solanezumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYSMSWVRQA PGKGLELVAQ  50
INSVGNSTYY PDTVKGRFTI SRDNAKNTLY LQMNSLRAED TAVYYCASGD 100
YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT 150
VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT QTYICNVNHK 200
PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR 350
DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G          441
Solanezumab|Light
DVVMTQSPLS LPVTLGQPAS ISCRSSQSLI YSDGNAYLHW FLQKPGQSPR  50
LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHVP 100
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219


Ramucirumab|Heavy
EVQLVQSGGG LVKPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSS  50
ISSSSSYIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARVT 100
DAFDIWGQGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
Ramucirumab|Light
DIQMTQSPSS VSASIGDRVT ITCRASQGID NWLGWYQQKP GKAPKLLIYD  50
ASNLDTGVPS RFSGSGSGTY FTLTISSLQA EDFAVYFCQQ AKAFPPTFGG 100
GTKVDIKGTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214


Cixutumumab|Heavy
EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWVRQA PGQGLEWMGG  50
IIPIFGTANY AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARAP 100
LRFLEWSTQD HYYYYYMDVW GKGTTVTVSS ASTKGPSVFP LAPSSKSTSG 150
GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT 200
VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG 250
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA 300
KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS 350
KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP 400
ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT 450
QKSLSLSPGK                                             460
Cixutumumab|Light
SSELTQDPAV SVALGQTVRI TCQGDSLRSY YATWYQQKPG QAPILVIYGE  50
NKRPSGIPDR FSGSSSGNTA SLTITGAQAE DEADYYCKSR DGSGQHLVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP AECS                                        214


Rontalizumab|Heavy
EVQLVESGGG LVQPGGSLRL SCATSGYTFT EYIIHWVRQA PGKGLEWVAS  50
INPDYDITNY NQRFKGRFTI SLDKSKRTAY LQMNSLRAED TAVYYCASWI 100
SDFFDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
Rontalizumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQSVS TSSYSYMHWY QQKPGKAPKV  50
LISYASNLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQHSWGIPR 100
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218


iodine (124I) girentuximab|Heavy
DVKLVESGGG LVKLGGSLKL SCAASGFTFS NYYMSWVRQT PEKRLELVAA  50
INSDGGITYY LDTVKGRFTI SRDNAKNTLY LQMSSLKSED TALFYCARHR 100
SGYFSMDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
iodine (124I) girentuximab|Light
DIVMTQSQRF MSTTVGDRVS ITCKASQNVV SAVAWYQQKP GQSPKLLIYS  50
ASNRYTGVPD RFTGSGSGTD FTLTISNMQS EDLADFFCQQ YSNYPWTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214


Fezakinumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYYMHWVRQA PGQGLEWVGW  50
INPYTGSAFY AQKFRGRVTM TRDTSISTAY MELSRLRSDD TAVYYCAREP 100
EKFDSDDSDV WGRGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
Fezakinumab|Light
QAVLTQPPSV SGAPGQRVTI SCTGSSSNIG AGYGVHWYQQ LPGTAPKLLI  50
YGDSNRPSGV PDRFSGSKSG TSASLAITGL QAEDEADYYC QSYDNSLSGY 100
VFGGGTQLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217


Glembatumumab|Heavy
QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SFNYYWSWIR HHPGKGLEWI  50
GYIYYSGSTY SNPSLKSRVT ISVDTSKNQF SLTLSSVTAA DTAVYYCARG 100
YNWNYFDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY 200
TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPVAGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300
VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP 350
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
Glembatumumab|Light
EIVMTQSPAT LSVSPGERAT LSCRASQSVD NNLVWYQQKP GQAPRLLIYG  50
ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YNNWPPWTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215


Dalotuzumab|Heavy
QVQLQQSGPG LVKPSQTLSL TCTVSGWSIS GGWLWNWIRQ PPGKGLQWIG  50
WISWDGTNNW KPSLKDRVTI SVDTSKNQFS LKLSSVTAAD TAVWWCARWG 100
RVFFDWWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
Dalotuzumab|Light
DIVMTQSPLS LPVTPGQPAS ISCRSSQSIV HSNGNTWLQW WLQKPGQSPQ  50
LLIWKVSNRL WGVPDRFSGS GSGTDFTLKI SRVQAQDVGV WWCFQGSHVP 100
WTFGQGTKVQ IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219

benralizumab|Heavy 
EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYVIHWVRQR PGQGLAWMGY  50
INPYNDGTKY NERFKGKVTI TSDRSTSTVY MELSSLRSED TAVYLCGREG 100
IRYYGLLGDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                      451
benralizumab|Light
DIQMTQSPSS LSASVGDRVT ITCGTSEDII NYLNWYQQKP GKAPKLLIYH  50
TSRLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GYTLPYTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214

               
Tralokinumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGLSWVRQA PGQGLEWMGW  50
ISANNGDTNY GQEFQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDS 100
SSSWARWFFD LWGRGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPS CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
Tralokinumab|Light
SYVLTQPPSV SVAPGKTARI TCGGNIIGSK LVHWYQQKPG QAPVLVIYDD  50
GDRPSGIPER FSGSNSGNTA TLTISRVEAG DEADYYCQVW DTGSDPVVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS                                        214


Drozitumab|Heavy
EVQLVQSGGG VERPGGSLRL SCAASGFTFD DYAMSWVRQA PGKGLEWVSG  50
INWQGGSTGY ADSVKGRVTI SRDNAKNSLY LQMNSLRAED TAVYYCAKIL 100
GAGRGWYFDY WGKGTTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                      451
Drozitumab|Light
SELTQDPAVS VALGQTVRIT CSGDSLRSYY ASWYQQKPGQ APVLVIYGAN  50
NRPSGIPDRF SGSSSGNTAS LTITGAQAED EADYYCNSAD SSGNHVVFGG 100
GTKLTVLGQP KAAPSVTLFP PSSEELQANK ATLVCLISDF YPGAVTVAWK 150
ADSSPVKAGV ETTTPSKQSN NKYAASSYLS LTPEQWKSHK SYSCQVTHEG 200
STVEKTVAPT ECS                                         213


Enokizumab|Heavy
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS YYWIEWVRQA PGQGLEWMGE  50
ILPGSGTTNP NEKFKGRVTI TADESTSTAY MELSSLRSED TAVYYCARAD 100
YYGSDYVKFD YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                     452
Enokizumab|Light
DIQMTQSPSS LSASVGDRVT ITCKASQHVI THVTWYQQKP GKAPKLLIYG  50
TSYSYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FYEYPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214


Etrolizumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFFIT NNYWGWVRQA PGKGLEWVGY  50
ISYSGSTSYN PSLKSRFTIS RDTSKNTFYL QMNSLRAEDT AVYYCARTGS 100
SGYFDFWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG     446
Etrolizumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASESVD DLLHWYQQKP GKAPKLLIKY  50
ASQSISGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GNSLPNTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Samalizumab|Heavy
QVQLQQSGSE LKKPGASVKI SCKASGYSFT DYIILWVRQN PGKGLEWIGH  50
IDPYYGSSNY NLKFKGRVTI TADQSTTTAY MELSSLRSED TAVYYCGRSK 100
RDYFDYWGQG TTLTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SNFGTQTYTC 200
NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LG         442
Samalizumab|Light
DIQMTQSPSS LSASIGDRVT ITCKASQDIN SYLSWFQQKP GKAPKLLIYR  50
ANRLVDGVPS RFSGSGSGTD YTLTISSLQP EDFAVYYCLQ YDEFPYTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214


Olaratumab|Heavy
QLQLQESGPG LVKPSETLSL TCTVSGGSIN SSSYYWGWLR QSPGKGLEWI  50
GSFFYTGSTY YNPSLRSRLT ISVDTSKNQF SLMLSSVTAA DTAVYYCARQ 100
STYYYGSGNY YGWFDRWDQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450
LSLSPGK                                                457
Olaratumab|Light
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPAFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214


Foralumab|Heavy
QVQLVESGGG VVQPGRSLRL SCAASGFKFS GYGMHWVRQA PGKGLEWVAV  50
IWYDGSKKYY VDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARQM 100
GYWHFDLWGR GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPEAEGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
Foralumab|Light
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPLTFG 100
GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215


gevokizumab|Heavy
QVQLQESGPG LVKPSQTLSL TCSFSGFSLS TSGMGVGWIR QPSGKGLEWL  50
AHIWWDGDES YNPSLKSRLT ISKDTSKNQV SLKITSVTAA DTAVYFCARN 100
RYDPPWFVDW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VTSSNFGTQT 200
YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVQFNWYVDG MEVHNAKTKP REEQFNSTFR 300
VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP IEKTISKTKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPMLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG      445
gevokizumab|Light
DIQMTQSTSS LSASVGDRVT ITCRASQDIS NYLSWYQQKP GKAVKLLIYY  50
TSKLHSGVPS RFSGSGSGTD YTLTISSLQQ EDFATYFCLQ GKMLPWTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214


oxelumab|Heavy
EVQLLESGGG LVQPGGSLRL SCAASGFTFN SYAMSWVRQA PGKGLEWVSI  50
ISGSGGFTYY ADSVKGRFTI SRDNSRTTLY LQMNSLRAED TAVYYCAKDR 100
LVAPGTFDYW GQGALVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
oxelumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214


Itolizumab|Heavy
EVQLVESGGG LVKPGGSLKL SCAASGFKFS RYAMSWVRQA PGKRLEWVAT  50
ISSGGSYIYY PDSVKGRFTI SRDNVKNTLY LQMSSLRSED TAMYYCARRD 100
YDLDYFDSWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
Itolizumab|Light
DIQMTQSPSS LSASVGDRVT ITCKASRDIR SYLTWYQQKP GKAPKTLIYY  50
ATSLADGVPS RFSGSGSGQD YSLTISSLES DDTATYYCLQ HGESPFTLGS 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214


ponezumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYYTE AYYIHWVRQA PGQGLEWMGR  50
IDPATGNTKY APRLQDRVTM TRDTSTSTVY MELSSLRSED TAVYYCASLY 100
SLPVYWGQGT TVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS NFGTQTYTCN 200
VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRVVSV 300
LTVVHQDWLN GKEYKCKVSN KGLPSSIEKT ISKTKGQPRE PQVYTLPPSR 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PMLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK         442
ponezumab|Light
DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL YSDAKTYLNW FQQRPGQSPR  50
RLIYQISRLD PGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQGTHYP 100
VLFGQGTRLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219


Ganitumab|Heavy
QVQLQESGPG LVKPSGTLSL TCAVSGGSIS SSNWWSWVRQ PPGKGLEWIG  50
EIYHSGSTNY NPSLKSRVTI SVDKSKNQFS LKLSSVTAAD TAVYYCARWT 100
GRTDAFDIWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
Ganitumab|Light
DVVMTQSPLS LPVTPGEPAS ISCRSSQSLL HSNGYNYLDW YLQKPGQSPQ  50
LLIYLGSNRA SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCMQGTHWP 100
LTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC


atinumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMSWVRQA PGKGLEWVAT  50
IKQDGSQKNY VDSVKGRFTI SRDNAKNSLY LRLNSLRAED TAVYYCATEL 100
FDLWGRGSLV TVSSASTKGP SVFPLAPCSR STSESTAALG CLVKDYFPEP 150
VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL GTKTYTCNVD 200
HKPSNTKVDK RVESKYGPPC PSCPAPEFLG GPSVFLFPPK PKDTLMISRT 250
PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTYRVVSVL 300
TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI SKAKGQPREP QVYTLPPSQE 350
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL 400
YSRLTVDKSR WQEGNVFSCS VMHEALHNHY TQKSLSLSLG K          441
atinumab|Light
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPITFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 


Radretumab|Heavy-Light
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SFSMSWVRQA PGKGLEWVSS  50
ISGSSGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPF 100
PYFDYWGQGT LVTVSSGDGS SGGSGGASEI VLTQSPGTLS LSPGERATLS 150
CRASQSVSSS FLAWYQQKPG QAPRLLIYYA SSRATGIPDR FSGSGSGTDF 200
TLTISRLEPE DFAVYYCQQT GRIPPTFGQG TKVEIKSGGS GGPRAAPEVY 250
AFATPEWPGS RDKRTLACLI QNFMPEDISV QWLHNEVQLP DARHSTTQPR 300
KTKGSGFFVF SRLEVTRAEW EQKDEFICRA VHEAASPSQT VQRAVSVNPE 350
SSRRGGC


Urelumab|Heavy
QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQS PEKGLEWIGE  50
INHGGYVTYN PSLESRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARDYG 100
PGNYDWYFDL WGRGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK   448
Urelumab|Light
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPALTF 100
CGGTKVEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW 150
KVDNALQSGN SQESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH 200
QGLSSPVTKS FNRGEC


Onartuzumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYWLHWVRQA PGKGLEWVGM  50
IDPSNSDTRF NPNFKDRFTI SADTSKNTAY LQMNSLRAED TAVYYCATYR 100
SYVTPLDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLVS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
Onartuzumab|Light
DIQMTQSPSS LSASVGDRVT ITCKSSQSLL YTSSQKNYLA WYQQKPGKAP  50
KLLIYWASTR ESGVPSRFSG SGSGTDFTLT ISSLQPEDFA TYYCQQYYAY 100
PWTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                  220


Ozoralizumab|Heavy-Heavy-Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYWMYWVRQA PGKGLEWVSE  50
INTNGLITKY PDSVKGRFTI SRDNAKNTLY LQMNSLRPED TAVYYCARSP 100
SGFNRGQGTL VTVSSGGGGS GGGSEVQLVE SGGGLVQPGN SLRLSCAASG 150
FTFSSFGMSW VRQAPGKGLE WVSSISGSGS DTLYADSVKG RFTISRDNAK 200
TTLYLQMNSL RPEDTAVYYC TIGGSLSRSS QGTLVTVSSG GGGSGGGSEV 250
QLVESGGGLV QPGGSLRLSC AASGFTFSDY WMYWVRQAPG KGLEWVSEIN 300
TNGLITKYPD SVKGRFTISR DNAKNTLYLQ MNSLRPEDTA VYYCARSPSG 350
FNRGQGTLVT VSS


Fulranumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTLR SYSMNWVRQA PGKGLEWVSY  50
ISRSSHTIFY ADSVKGRFTI SRDNAKNSLY LQMDSLRDED TAMYYCARVY 100
SSGWHVSDYF DYWGQGILVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSNFG 200
TQTYTCNVDH KPSNTKVDKT VERKCCVECP PCPAPPVAGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TFRVVSVLTV VHQDWLNGKE YKCKVSNKGL PAPIEKTISK TKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPML 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
Fulranumab|Light
AIQLTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYD  50
ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC  


Tregalizumab|Heavy
EEQLVESGGG LVKPGGSLRL SCAASGFSFS DCRMYWLRQA PGKGLEWIGV  50
ISVKSENYGA NYAESVRGRF TISRDDSKNT VYLQMNSLKT EDTAVYYCSA 100
SYYRYDVGAW FAYWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                   454
Tregalizumab|Light
DIVMTQSPDS LAVSLGERAT INCRASKSVS TSGYSYIYWY QQKPGQPPKL  50
LIYLASILES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQHSRELPW 100
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC


Narnatumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYLMTWVRQA PGKGLEWVAN  50
IKQDGSEKYY VDSVKGRFTI SRDNAKNSLN LQMNSLRAED TAVYYCTRDG 100
YSSGRHYGMD VWGQGTTVIV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                     452
Narnatumab|Light
EIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 


Ixekizumab|Heavy
QVQLVQSGAE VKKPGSSVKV SCKASGYSFT DYHIHWVRQA PGQGLEWMGV  50
INPMYGTTDY NQRFKGRVTI TADESTSTAY MELSSLRSED TAVYYCARYD 100
YFTGTGVYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLG      445
Ixekizumab|Light
DIVMTQTPLS LSVTPGQPAS ISCRSSRSLV HSRGNTYLHW YLQKPGQSPQ  50
LLIYKVSNRF IGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHLP 100
FTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC 


Abituzumab|Heavy
QVQLQQSGGE LAKPGASVKV SCKASGYTFS SFWMHWVRQA PGQGLEWIGY 50
INPRSGYTEY NEIFRDKATM TTDTSTSTAY MELSSLRSED TAVYYCASFL 100
GRGAMDYWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVEPKS SDKTHTCPPC PAPPVAGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQAQSTF 300
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
Abituzumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NYLAWYQQKP GKAPKLLIYY  50
TSKIHSGVPS RFSGSGSGTD YTFTISSLQP EDIATYYCQQ GNTFPYTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC  


Ontuxizumab|Heavy
QVQLQESGPG LVRPSQTLSL TCTASGYTFT DYVIHWVKQP PGRGLEWIGY  50
INPYDDDTTY NQKFKGRVTM LVDTSSNTAY LRLSSVTAED TAVYYCARRG 100
NSYDGYFDYS MDYWGSGTPV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGF FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                   454
Ontuxizumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQNVG TAVAWLQQTP GKAPKLLIYS  50
ASNRYTGVPS RFSGSGSGTD YTFTISSLQP EDIATYYCQQ YTNYPMYTFG 100
QGTKVQIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC 


Romosozumab|Heavy
EVQLVQSGAE VKKPGASVKV SCKASGYTFT DYNMHWVRQA PGQGLEWMGE  50
INPNSGGAGY NQKFKGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARLG 100
YDDIYDDWYF DVWGQGTTVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSNFG 200
TQTYTCNVDH KPSNTKVDKT VERKCCVECP PCPAPPVAGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TFRVVSVLTV VHQDWLNGKE YKCKVSNKGL PAPIEKTISK TKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPML 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
Romosozumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NYLNWYQQKP GKAPKLLIYY  50
TSRLLSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GDTLPYTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Quilizumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYGIAWVRQA PGKGLEWVAF  50
ISDLAYTIYY ADTVTGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDN 100
WDAMDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
Quilizumab|Light
DIQMTQSPSS LSASVGDRVT ITCRSSQSLV HNNANTYLHW YQQKPGKAPK  50
LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCSQNTLVP 100
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC 


Actoxumab|Heavy
QVQLVESGGG VVQPGRSLRL SCAASGFSFS NYGMHWVRQA PGKGLEWVAL  50
IWYDGSNEDY TDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARWG 100
MVRGVIDVFD IWGQGTVVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                     452
Actoxumab|Light
DIQMTQSPSS VSASVGDRVT ITCRASQGIS SWLAWYQHKP GKAPKLLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC  


Enoticumab|Heavy
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVSF  50
LWYDGTNKNY VESVKGRFTI SRDNSKNMLY LEMNSLRAED TAVYYCARDH 100
DFRSGYEGWF DPWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PG                                                     452
Enoticumab|Light
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQH RSNWPPTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Lampalizumab|Heavy
EVQLVQSGPE LKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW  50
INTYTGETTY ADDFKGRFVF SLDTSVSTAY LQISSLKAED TAVYYCEREG 100
GVNNWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THT                              223
Lampalizumab|Light
DIQVTQSPSS LSASVGDRVT ITCITSTDID DDMNWYQQKP GKVPKLLISG  50 
GNTLRPGVPS RFSGSGSGTD FTLTISSLQP EDVATYYCLQ SDSLPYTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Fasinumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKVSGFTLT ELSIHWVRQA PGKGLEWMGG  50
FDPEDGETIY AQKFQGRVTM TEDTSTDTAY MELTSLRSED TAVYYCSTIF 100
GVVTNFDNWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK     446
Fasinumab|HLight
DIQMTQSPSS LSASAGDRVT ITCRASQAIR NDLGWYQQKP GKAPKRLIYA  50
AFNLQSGVPS RFSGSGSGTE FTLTISSLQP EDLASYYCQQ YNRYPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 


Bezlotoxumab|Heavy
EVQLVQSGAE VKKSGESLKI SCKGSGYSFT SYWIGWVRQM PGKGLEWMGI  50
FYPGDSSTRY SPSFQGQVTI SADKSVNTAY LQWSSLKASD TAMYYCARRR 100
NWGNAFDIWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
Bezlotoxumab|HLight
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSTWTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC 


Futuximab|Heavy
EVQLQQPGSE LVRPGASVKL SCKASGYTFT SYWMHWVKQR PGQGLEWIGN  50
IYPGSRSTNY DEKFKSKATL TVDTSSSTAY MQLSSLTSED SAVYYCTRNG 100
DYYVSSGDAM DYWGQGTSVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PG                                                     452
Futuximab|Light
DIQMTQTTSS LSASLGDRVT ISCRTSQDIG NYLNWYQQKP DGTVKLLIYY  50
TSRLHSGVPS RFSGSGSGTD FSLTINNVEQ EDVATYFCQH YNTVPPTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 


Modotuximab|Heavy
QVQLQQPGAE LVEPGGSVKL SCKASGYTFT SHWMHWVKQR PGQGLEWIGE  50
INPSSGRNNY NEKFKSKATL TVDKSSSTAY MQFSSLTSED SAVYYCVRYY 100
GYDEAMDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG   448
Modotuximab|Light
DIVMTQAAFS NPVTLGTSAS ISCRSSKSLL HSNGITYLYW YLQKPGQSPQ  50
LLIYQMSNLA SGVPDRFSSS GSGTDFTLRI SRVEAEDVGV YYCAQNLELP 100
YTFGGGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC


nivolumab|Heavy
QVQLVESGGG VVQPGRSLRL DCKASGITFS NSGMHWVRQA PGKGLEWVAV  50
IWYDGSKRYY ADSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCATND 100
DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV 150
TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH 200
KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP KDTLMISRTP 250
EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN STYRVVSVLT 300
VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE 350
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY 400
SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK            440
nivolumab|Light
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ SSNWPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Evolocumab|Heavy
EVQLVQSGAE VKKPGASVKV SCKASGYTLT SYGISWVRQA PGQGLEWMGW  50
VSFYNGNTNY AQKLQGRGTM TTDPSTSTAY MELRSLRSDD TAVYYCARGY 100
GMDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSN FGTQTYTCNV 200
DHKPSNTKVD KTVERKCCVE CPPCPAPPVA GPSVFLFPPK PKDTLMISRT 250
PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL 300
TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLPPSRE 350
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL 400
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K          441
Evolocumab|Light
ESALTQPASV SGSPGQSITI SCTGTSSDVG GYNSVSWYQQ HPGKAPKLMI  50
YEVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC NSYTSTSMVF 100
GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
EGSTVEKTVA PTECS 


perakizumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYTMLWVRQA PGKGLEWVAI  50
IKSGGSYSYY PDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARDG 100
DYGSSYGAMD YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPEAA GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                     452
perakizumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQDIN SYLSWFQQKP GKAPKSLIVR  50
ANRLVDGVPS RFSGSGSGQD YSLTISSLQP EDFATYYCLQ YDAFPPYTFG 100
QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC


Dinutuximab|Heavy
EVQLLQSGPE LEKPGASVMI SCKASGSSFT GYNMNWVRQN IGKSLEWIGA  50
IDPYYGGTSY NQKFKGRATL TVDKSSSTAY MHLKSLTSED SAVYYCVSGM 100
EYWGQGTSVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV 150
TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TQTYICNVNH 200
KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS 350
REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK        443                                          
Dinutuximab|Light
EIVMTQSPAT LSVSPGERAT LSCRSSQSLV HRNGNTYLHW YLQKPGQSPK  50
LLIHKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDLGV YFCSQSTHVP 100
PLTFGAGTKL ELKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC


Tarextumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SSGMSWVRQA PGKGLEWVSV  50
IASSGSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARSI 100
FYTTWGQGTL VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSN FGTQTYTCNV 200
DHKPSNTKVD KTVERKCCVE CPPCPAPPVA GPSVFLFPPK PKDTLMISRT 250
PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL 300
TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLPPSRE 350
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL 400
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K          441
Tarextumab|Light
DIVLTQSPAT LSLSPGERAT LSCRASQSVR SNYLAWYQQK PGQAPRLLIY  50
GASSRATGVP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QYSNFPITFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC


Tovetumab|Heavy
QVQLVESGGG LVKPGGSLRL SCAASGFTFS DYYMNWIRQA PGKGLEWVSY  50
ISSSGSIIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG 100
RIAARGMDVW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT 200
YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTFR 300
VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP IEKTISKTKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPMLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
Tovetumab|Light
DIQMTQSPSS LSASVGDRVS ITCRPSQSFS RYINWYQQKP GKAPKLLIHA  50
ASSLVGGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSNPPITFG 100
QGTRLEMKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC


vantictumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS HYTLSWVRQA PGKGLEWVSV  50
ISGDGSYTYY ADSVKGRFTI SSDNSKNTLY LQMNSLRAED TAVYYCARNF 100
IKYVFANWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPG        443
vantictumab|Light
DIELTQPPSV SVAPGQTARI SCSGDNIGSF YVHWYQQKPG QAPVLVIYDK  50
SNRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY ANTLSLVFGG 100
GTKLTVLGQP KAAPSVTLFP PSSEELQANK ATLVCLISDF YPGAVTVAWK 150
ADSSPVKAGV ETTTPSKQSN NKYAASSYLS LTPEQWKSHR SYSCQVTHEG 200
STVEKTVAPT ECS


pembrolizumab|Heavy
QVQLVQSGVE VKKPGASVKV SCKASGYTFT NYYMYWVRQA PGQGLEWMGG  50
INPSNGGTNF NEKFKNRVTL TTDSSTTTAY MELKSLQFDD TAVYYCARRD 100
YRFDMGFDYW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200
YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK    447
pembrolizumab|Light
EIVLTQSPAT LSLSPGERAT LSCRASKGVS TSGYSYLHWY QQKPGQAPRL  50
LIYLASYLES GVPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQHSRDLPL 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC			


Atezolizumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DSWIHWVRQA PGKGLEWVAW  50
ISPYGGSTYY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARRH 100
WPGGFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYAST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK	 448
Atezolizumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP GKAPKLLIYS  50
ASFLYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YLYHPATFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Bococizumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYYMHWVRQA PGQGLEWMGE  50
ISPFGGRTNY NEKFKSRVTM TRDTSTSTVY MELSSLRSED TAVYYCARER 100
PLYASDLWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPSSIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK       444 
Bococizumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYS  50
ASYRYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ RYSLWRTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Ralpancizumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYYMHWVRQA PGQGLEWMGE  50
IHPSGGRTNY NEKFKSRVTM TRDTSTSTVY MELSSLRSED TAVYYCARER 100
PLYASDLWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPSSIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK       444
Ralpancizumab|Light
DIQMTQSPSS LSASVGDRVT ITCKASQDVH TAVAWYQQKP GKAPKLLIYH  50
ASYRYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ RYSLWRTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Ulocuplumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAAAGFTFS SYSMNWVRQA PGKGLEWVSY  50
ISSRSRTIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRDED TAVYYCARDY 100
GGQPPYYYYY GMDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350
PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450
G                                                      451
Ulocuplumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFVTYYCQQ YNSYPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 


Abrilumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKVSGYTLS DLSIHWVRQA PGKGLEWMGG  50
FDPQDGETIY AQKFQGRVTM TEDTSTDTAY MELSSLKSED TAVYYCATGS 100
SSSWFDPWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK       444
Abrilumab|Light
DIQMTQSPSS VSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKLLIYG  50
ASNLESGVPS RFSGSGSGTD FTLTISSLQP EDFANYYCQQ ANSFPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC

Emactuzumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYDISWVRQA PGQGLEWMGV  50
IWTDGGTNYA QKLQGRVTMT TDTSTSTAYM ELRSLRSDDT AVYYCARDQR 100
LYFDVWGQGT TVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
Emactuzumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASEDVN TYVSWYQQKP GKAPKLLIYA  50
ASNRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SFSYPTFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 


Navivumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKTSGYSFS TYGVSWVRQA PGQGPEWVGW  50
ISAYTGITDY AQKFQGRVTL TTDATTATAF LDLRSLRPDD TATYFCARDK 100
VQGRVEVGSG GRHDYWGQGT LVIVSSASTK GPSVFPLAPS SKSTSGGTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF 250
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG 350
QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 400
KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEG LHNHYTQKSL 450
SLSPGK                                                 456
Navivumab|Light
EVVLTQSPGT LALPPGERAT LSCRASHRVG STYIAWYQQK SGQAPRRLIY  50
GASNRATDIP DRFSGSGSGT DFTLTIRRLE PEDSAVYYCQ QFSVSPWTFG 100
QGTRVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC 
 

Inebilizumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SSWMNWVRQA PGKGLEWVGR  50
IYPGDGDTNY NVKFKGRFTI SRDDSKNSLY LQMNSLKTED TAVYYCARSG 100
FITTVRDFDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                      451
Inebilizumab|Light
EIVLTQSPDF QSVTPKEKVT ITCRASESVD TFGISFMNWF QQKPDQSPKL  50
LIHEASNQGS GVPSRFSGSG SGTDFTLTIN SLEAEDAATY YCQQSKEVPF 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC




Andecaliximab|Heavy
QVQLQESGPG LVKPSETLSL TCTVSGFSLL SYGVHWVRQP PGKGLEWLGV  50
IWTGGTTNYN SALMSRFTIS KDDSKNTVYL KMNSLKTEDT AIYYCARYYY 100
GMDYWGQGTL VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV 200
DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL GK         442
Andecaliximab|Light
DIQMTQSPSS LSASVGDRVT ITCKASQDVR NTVAWYQQKP GKAPKLLIYS  50
SSYRNTGVPD RFSGSGSGTD FTLTISSLQA EDVAVYYCQQ HYITPYTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Lendalizumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYSMDWVRQA PGQGLEWMGA  50
IHLNTGYTNY NQKFKGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARGF 100
YDGYSPMDYW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT 200
YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK     446
Lendalizumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASESVD SYGNSFMHWY QQKPGKAPKL  50
LIYRASNLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPY 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC


Elgemtumab|Heavy
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA  50
INSQGKSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARWG 100
DEGFDIWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
Elgemtumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQGIS NWLAWYQQKP GKAPKLLIYG  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSSFPTTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 


Tesidolumab|Heavy
EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWVRQA PGQGLEWMGG  50
IGPFFGTANY AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARDT 100
PYFDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PEAAGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
Tesidolumab|Light
SYELTQPLSV SVALGQTARI TCSGDSIPNY YVYWYQQKPG QAPVLVIYDD  50
SNRPSGIPER FSGSNSGNTA TLTISRAQAG DEADYYCQSF DSSLNAEVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS


nemolizumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYIMNWVRQA PGQGLEWMGL  50
INPYNGGTDY NPQFQDRVTI TADKSTSTAY MELSSLRSED TAVYYCARDG 100
YDDGPYTLET WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ 200
TYTCNVDHKP SNTKVDKTVE RKSCVECPPC PAPPVAGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF 300
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT 350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS 400
DGSFFLYSKL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSP      445
nemolizumab|Light
DIQMTQSPSS LSASVGDRVT ITCQASEDIY SFVAWYQQKP GKAPKLLIYN  50
AQTEAQGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQH HYDSPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 


Sapelizumab|Heavy
QVQLQESGPG LVKPSETLSL TCAVSGHSIS HDHAWSWVRQ PPGEGLEWIG  50
FISYSGITNY NPSLQGRVTI SRDNSKNTLY LQMNSLRAED TAVYYCARSL 100
ARTTAMDYWG EGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY 200
TCNVDHKPSN TKVDKTVERK SCVECPPCPA PPVAGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300
VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP 350
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400
SFFLYSKLTV DKSRWQEGNV FSCSVMHEAL HAHYTQKSLS LSP        443
Sapelizumab|Light
DIQMTQSPSS LSASVGDSVT ITCQASTDIS SHLNWYQQKP GKAPELLIYY  50
GSHLLSGVPS RFSGSGSGTD FTFTISSLEA EDAATYYCGQ GNRLPYTFGQ 100
GTKVEIERTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Isatuximab|Heavy
QVQLVQSGAE VAKPGTSVKL SCKASGYTFT DYWMQWVKQR PGQGLEWIGT  50
IYPGDGDTGY AQKFQGKATL TADKSSKTVY MHLSSLASED SAVYYCARGD 100
YYGSNSLDYW GQGTSVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
Isatuximab|Light
DIVMTQSHLS MSTSLGDPVS ITCKASQDVS TVVAWYQQKP GQSPRRLIYS  50
ASYRYIGVPD RFTGSGAGTD FTFTISSVQA EDLAVYYCQQ HYSPPYTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Lilotomab|Heavy
EIQLQQSGPE LVKPGASVKV SCKASGYSFT DYNMYWVKQS HGKSLEWIGY  50
IDPYNGDTTY NQKFKGKATL TVDKSSSTAF IHLNSLTSED SAVYYCARSP 100
YGHYAMDYWG QGTSVTVSSA KTTPPSVYPL APGSAAQTNS MVTLGCLVKG 150
YFPEPVTVTW NSGSLSSGVH TFPAVLQSDL YTLSSSVTVP SSTWPSETVT 200
CNVAHPASST KVDKKIVPRD CGCKPCICTV PEVSSVFIFP PKPKDVLTIT 250
LTPKVTCVVV DISKDDPEVQ FSWFVDDVEV HTAQTQPREE QFNSTFRSVS 300
ELPIMHQDWL NGKEFKCRVN SAAFPAPIEK TISKTKGRPK APQVYTIPPP 350
KEQMAKDKVS LTCMITDFFP EDITVEWQWN GQPAENYKNT QPIMDTDGSY 400
FVYSKLNVQK SNWEAGNTFT CSVLHEGLHN HHTEKSLSHS PGK        443
Lilotomab|Light
DIVMTQSHKL LSTSVGDRVS ITCKASQDVS TAVDWYQQKP GQSPKLLINW  50
ASTRHTGVPD RFTGSGSGTD YTLTISSMQA EDLALYYCRQ HYSTPFTFGS 100
GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150
DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200
STSPIVKSFN RNEC



Indusatumab|Heavy
QVQLQQWGAG LLKPSETLSL TCAVFGGSFS GYYWSWIRQP PGKGLEWIGE  50
INHRGNTNDN PSLKSRVTIS VDTSKNQFAL KLSSVTAADT AVYYCARERG 100
YTYGNFDHWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
Indusatumab|Light
EIVMTQSPAT LSVSPGERAT LSCRASQSVS RNLAWYQQKP GQAPRLLIYG  50
ASTRATGIPA RFSGSGSGTE FTLTIGSLQS EDFAVYYCQQ YKTWPRTFGQ 100
GTNVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 



Ifabotuzumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYWMNWVRQA PGQGLEWMGD  50
IYPGSGNTNY DEKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARGG 100
YYEDFDSWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
Ifabotuzumab|Light
DIQMTQSPSF LSASVGDRVT ITCRASQGII SYLAWYQQKP EKAPKRLIYA  50
ASSLQSGVPS RFSGSGSGTE FTLTISSLQP EDFATYYCGQ YANYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC


Rinucumab|Heavy
QLQLQESGPG LVKPSETLSL TCTVSGGSIT SSSYYWGWIR QPPGKGLEWI  50
GSIYYRGSTN YNPSLKSRVT ISVDSSKNQF YLKVSSVTAV DTAVYYCARQ 100
NGAARPSWFD PWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
Rinucumab|Light
EIVLTQSPDT ISLSPGERAT LSCRASQSIS SIYLAWYQQK PGQAPRLLIY  50
GASSRVTGIP DRFSVSGSGT DFTLTISRLE PEDFAVYYCQ HYGISPFTFG 100
PGTKVDIRRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC


Rivabazuma|Heavy
EVQLVESGGG VVQPGRSLRL SCAASGFTFS NYPMHWVRQA PGKGLEWVAV  50 
ISYDGSEKWY ADSVKGRFTI SRDNSKNTLY LEMNSLRPED TAVYYCARNR 100 
GDIYYDFTYA MDIWGQGTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150 
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200 
GTQTYICNVN HKPSNTKVDK KVEPKSSDKT HTCPPCPA              238
Rivabazuma|Light
DIQLTQSPST LSASVGDSVT ITCRASEGVD RWLAWYQQKP GRAPKLLIYD  50 
ASTLQSGVPS RFSGSGSGTE FSLTISSLQP DDVATYYCQH FWGTPYTFGQ 100 
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 
LSSPVTKSFN RGES 


Prezalumab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYWMSWVRQA PGKGLEWVAY  50 
IKQDGNEKYY VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG 100 
ILWFGDLPTF WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150 
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ 200 
TYTCNVDHKP SNTKVDKTVE RKCCVECPPC PAPPVAGPSV FLFPPKPKDT 250 
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF 300 
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT 350 
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS 400 
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
Prezalumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQGIS NWLAWYQQKP EKAPKSLIYA  50 
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDSYPRTFGQ 100 
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 
LSSPVTKSFN RGEC 


Lanadelumab|Heavy
EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYIMMWVRQA PGKGLEWVSG  50 
IYSSGGITVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAYRR 100 
IGVPRRDEFD IWGQGTMVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150 
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200 
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250 
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300 
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350 
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400 
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450 
G                                                      451 
Lanadelumab|Light
DIQMTQSPST LSASVGDRVT ITCRASQSIS SWLAWYQQKP GKAPKLLIYK  50 
ASTLESGVPS RFSGSGSGTE FTLTISSLQP DDFATYYCQQ YNTYWTFGQG 100 
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150 
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200 
SSPVTKSFNR GEC 


Pogalizumab|Heavy
EVQLVQSGAE VKKPGASVKV SCKASGYTFT DSYMSWVRQA PGQGLEWIGD  50 
MYPDNGDSSY NQKFRERVTI TRDTSTSTAY LELSSLRSED TAVYYCVLAP 100 
RWYFSVWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250 
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300 
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350 
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
Pogalizumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NYLNWYQQKP GKAPKLLIYY  50 
TSRLRSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GHTLPPTFGQ 100 
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 
LSSPVTKSFN RGEC 


Domagrozumab|Heavy
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVST  50 
ISSGGSYTSY PDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQD 100 
YAMNYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150 
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200 
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PEAAGAPSVF LFPPKPKDTL 250 
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300 
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350 
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400 
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446 
Domagrozumab|Light
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS  50 
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSTPWTFGG 100 
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 
LSSPVTKSFN RGEC 


Emapalumab|Heavy
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA  50
ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDG 100
SSGWYVPHWF DPWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                    453
Emapalumab|Light
NFMLTQPHSV SESPGKTVTI SCTRSSGSIA SNYVQWYQQR PGSSPTTVIY  50
EDNQRPSGVP DRFSGSIDSS SNSASLTISG LKTEDEADYY CQSYDGSNRW 100
MFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS 


Elezanumab|Heavy
EVQLVQSGAE VKKPGASVKV SCKASGYTFT SHGISWVRQA PGQGLDWMGW  50
ISPYSGNTNY AQKLQGRVTM TTDTSTSTAY MELSSLRSED TAVYYCARVG 100
SGPYYYMDVW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPEAAGG PSVFLFPPKP 250
KDQLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHNHYT QKSLSLSPGK 450
Elezanumab|Light
QSALTQPRSV SGSPGQSVTI SCTGTSSSVG DSIYVSWYQQ HPGKAPKLML  50
YDVTKRPSGV PDRFSGSKSG NTASLTISGL QAEDEADYYC YSYAGTDTLF 100
GGGTKVTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
EGSTVEKTVA PTECS

Remtolumab|Heavy
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSA  50
ITWNSGHIDY ADSVEGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAKVS 100
YLSTASSLDY WGQGTLVTVS SGGGGSGGGG SEVQLVQSGA EVKKPGSSVK 150
VSCKASGGSF GGYGIGWVRQ APGQGLEWMG GITPFFGFAD YAQKFQGRVT 200
ITADESTTTA YMELSGLTSD DTAVYYCARD PNEFWNGYYS THDFDSWGQG 250
TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS 300
GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK 350
VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT 400
CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH 450
QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK 500
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL 550
TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK               587
Remtolumab|Light
DIQMTQSPSS LSASVGDRVT ITCRASQGIR NYLAWYQQKP GKAPKLLIYA  50
ASTLQSGVPS RFSGSGSGTD FTLTISSLQP EDVATYYCQR YNRAPYTFGQ 100
GTKVEIKRGG SGGGGSGEIV LTQSPDFQSV TPKEKVTITC RASQDIGSEL 150
HWYQQKPDQP PKLLIKYASH STSGVPSRFS GSGSGTDFTL TINGLEAEDA 200
GTYYCHQTDS LPYTFGPGTK VDIKRTVAAP SVFIFPPSDE QLKSGTASVV 250
CLLNNFYPRE AKVQWKVDNA LQSGNSQESV TEQDSKDSTY SLSSTLTLSK 300
ADYEKHKVYA CEVTHQGLSS PVTKSFNRGE C 


Telisotuzumab|Heavy
QVQLVQSGAE VKKPGASVKV SCKASGYIFT AYTMHWVRQA PGQGLEWMGW  50
IKPNNGLANY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARSE 100
ITTEFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDCHCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG      445
Telisotuzumab|Light
DIVMTQSPDS LAVSLGERAT INCKSSESVD SYANSFLHWY QQKPGQPPKL  50
LIYRASTRES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEDPL 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC


Aprutumab|Heavy
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA  50
ISGSGTSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVR 100
YNWNHGDWFD PWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
G                                                      451
Aprutumab|Light
QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY  50
ENYNRPAGVP DRFSGSKSGT SASLAISGLR SEDEADYYCS SWDDSLNYWV 100
FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS 


Brazikumab|Heavy
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV  50
IWYDGSNEYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDR 100
GYTSSWYPDA FDIWGQGTMV TVSSASTKGP SVFPLAPCSR STSESTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSNF 200
GTQTYTCNVD HKPSNTKVDK TVERKCCVEC PPCPAPPVAG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STFRVVSVLT VVHQDWLNGK EYKCKVSNKG LPAPIEKTIS KTKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
Brazikumab|Light
QSVLTQPPSV SGAPGQRVTI SCTGSSSNTG AGYDVHWYQQ VPGTAPKLLI  50
YGSGNRPSGV PDRFSGSKSG TSASLAITGL QAEDEADYYC QSYDSSLSGW 100
VFGGGTRLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS
